Annidis Corporation  

(Public, CVE:RHA)   Watch this stock  
Find more results for cve:rha
0.280
0.000 (0.00%)
Delayed:   3:01PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.16 - 0.35
Open     -
Vol / Avg. 0.00/8,661.00
Mkt cap 24.85M
P/E     -
Div/yield     -
EPS -0.06
Shares 88.74M
Beta -1.49
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -155.67% -403.88%
Operating margin -130.52% -319.56%
EBITD margin - -298.91%
Return on average assets -146.58% -155.88%
Return on average equity - -
CDP Score - -

Address

Suite 245, 2650 Queensview Drive
OTTAWA, ON K2B 8H6
Canada
+1-519-6721524 (Phone)
+1-519-6726950 (Fax)

Website links

Description

Annidis Corporation is engaged in the research, development and sale of a medical device to eye-care professionals in Canada and the United States. The Company provides technology for early stage diagnosis of eye disease and develops instrumentation to assist in the early detection and monitoring of diseases of the eye. The Company´┐Żs RHA is an ocular pathology management system that integrates advanced multi-spectral imaging and analytic software for early detection and management of ocular pathologies, such as glaucoma, age related macular degeneration and diabetic retinopathy. The Company has also developed an imaging platform technology based on Multi-Spectral Imaging (MSI). MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye and provides for earlier identification and the treatment of debilitating eye diseases. Effective January 1, 2014, Annidis Corporation amalgamated with its wholly owned subsidiary Annidis Health Systems Corp.

Officers and directors

Michael P. Mueller Chairman of the Board
Zeljko Ribaric President, Director
Gerald Slemko Chief Executive Officer, Director
Age: 59
Brian Baker Chief Financial Officer
Michael Francis Crowley Independent Director
Robert G. Devenyi Independent Director
Rony Thomas Independent Director